Response of combination therapy on viral load and disease severity in chronic hepatitis C

Digestive Diseases and Sciences

Volumn 53, Issue 4, 2008, Pages 1107-1113

  Kumar, Deepak ^a,b   Malik, Abdul ^a   Asim, Mohammad ^a   Chakravarti, Anita ^a   Das, Rakha H ^b   Kar, Premashis ^a,c  

^a MAULANA AZAD MEDICAL COLLEGE   (India)

^b CSIR INSTITUTE OF GENOMICS AND INTEGRATIVE BIOLOGY   (India)

^c NONE   (India)

Author keywords

Hepatitis C virus; Histological activity index; Interferon therapy; RFLP; Virological response

Indexed keywords

REBETRON;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; LIVER DISEASE; MALE; PRIORITY JOURNAL; SCREENING; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; RIBAVIRIN; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VIRAL LOAD;

EID: 40749099052     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-007-9960-8     Document Type: Article

References (25)

1. Kim WR (2002) The burden of hepatitis C in the United States. Hepatol 36:S30-S34
2. Panigrahi AK, Panda SK, Dixit RK, Rao KV, Acharya SK, Dasarathy S, Nanu A (1997) Magnitude of hepatitis C virus infection in India: prevalence in healthy blood donors, acute and chronic liver diseases. J Med Virol 51:167-174
3. Hissar SS, Goyal A, Kumar M, Pandey C, Suneetha PV, Sood A, Midha V, Sakhuja P, Malhotra V, Sarin SK (2006) Hepatitis C virus genotype 3 predominates in North and Central India and is associated with significant histopathologic liver disease. J Med Virol 78:452-458
4. Rothman AL, Morishima C, Bonkovsky HL, Polyak SJ, Ray R, Di Bisceglie AM, Lindsay KL, Malet PF, Chang M, Gretch DR, Sullivan DG, Bhan AK, Wright EC, Koziel MJ, HALT-C Trial Group (2005) Associations among clinical, immunological, and viral quasispecies measurements in advanced chronic hepatitis C. Hepatol 41:617-625
5. Martinot-Peignoux M, Marcellin P, Pouteau M, Castelnau C, Boyer N, Poliquin M, Degott C, Descombes I, Le Breton V, Milotova V et al (1995) Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatol 22:1050-1056
6. Dalgard O, Mangia A (2006) Short-term therapy for patients with hepatitis C virus genotype 2 or 3 infection. Drugs 66:1807-1815
7. Hazari S, Panda SK, Gupta SD, Batra Y, Singh R, Acharya SK (2004) Treatment of hepatitis C virus infection in patients of northern India. J Gastroenterol Hepatol 19:1058-1065
8. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, Shiffman ML, Zeuzem S, Craxi A, Ling MH, Albrecht J (1998) Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 339:1493-1499
9. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J (1981) Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatol 1(5):431-435
10. Chinchai T, Labout J, Noppornpanth S, Theamboonlers A, Haagmans BL, Osterhaus AD, Poovorawan Y (2003) Comparative study of different methods to genotype hepatitis C virus type 6 variants. J Virol Methods 109:195-201
11. Chenna R, Sugawara H, Koike T, Lopez R, Gibson TJ, Higgins DG, Thompson JD (2003) Multiple sequence alignment with the Clustal series of programs. Nucleic Acids Res 31:3497-3500
12. Gerken G, Knolle P, Jakobs S, Meyer zum Buschenfelde KH (1997) Quantification and genotyping of serum HCV-RNA in patients with chronic hepatitis C undergoing interferon treatment. Arch Virol 142:459-464
13. Legrand-Abravanel F, Sandres-Saune K, Barange K, Alric L, Moreau J, Desmorat P, Vinel JP, Izopet J (2004) Hepatitis C virus genotype 5: epidemiological characteristics and sensitivity to combination therapy with interferon-alpha plus ribavirin. J Infect Dis 189:1397-1400
14. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK (1998) Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 339:1485-1492
15. Bukh J, Miller RH, Purcell RH (1995) Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis 15(1):41-63
16. Zeuzem S (2004) Heterogeneous virological response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? Ann Intern Med 140(5):370-381
17. Martins RM, Teles SA, Freitas NR, Motta-Castro AR, Souto FJ, Mussi A, Amorim RM, Martins CR (2006) Distribution of hepatitis C virus genotypes among blood donors from mid-west region of Brazil. Rev Inst Med Trop Sao Paulo 48(1):53-55
18. Stuyver L, Wyseur A, van Arnhem W, Lunel F, Laurent-Puig P, Pawlotsky JM, Kleter B, Bassit L, Nkengasong J, van Doorn LJ et al (1995) Hepatitis C virus genotyping by means of 5′-UR/core line probe assays and molecular analysis of untypeable samples. Virus Res 38:137-157
19. Gracia-Samaniego J, Soriano V, Castill J, Braco R, Moreno A, Carbo J (1997) Influence of hepatitis C virus genotypes and HIV infection on histological severity of chronic hepatitis C. Am J Gasteroenterol 92:1130-1134
20. Khaja MN, Madhavi C, Thippavazzula R, Nafeesa F, Habib AM, Habibullah CM, Guntaka RV (2005) High prevalence of hepatitis C virus infection and genotype distribution among general population, blood donors and risk groups. Infect Genet Evol 6(3):198-204
21. Brechot C (1994) Hepatitis C virus genetic variability clinical implications. Am J Gastroenterol 89:S41-S47
22. De Moliner L, Pontisso P, De Salvo GL, Cavalletto L, Chemello L, Alberti A (1998) Serum and liver HCV RNA levels in patients with chronic hepatitis C: correlation with clinical and histological features. Gut 42(6):856-860
23. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347(13):975-982
24. Missale G, Cariani E, Lamonaca V, Ravaggi A, Rossini A, Bertoni R, Houghton M, Matsuura Y, Miyamura T, Fiaccadori F, Ferrari C (1997) Effects of interferon treatment on the antiviral T-cell response in hepatitis C virus genotype 1b- and genotype 2c-infected patients. Hepatology 26(3):792-797
25. Adinolfi LE, Utili R, Andreana A, Tripodi MF, Marracino M, Gambardella M, Giordano M, Ruggiero G (2001) Serum HCV RNA levels correlate with histological liver damage and concur with steatosis in progression of chronic hepatitis C. Dig Dis Sci 46(8):1677-1683